The year posed many challenges, but cannabis businesses, research centers, and reform groups still managed to make impressive headway. Analytical Cannabis looks back on the stories and issues that dominated the cannabis industry in 2021.
Kimberly Ross of Peak Compliance Labs outlines the many obstacles hemp faces before it becomes fully regulated in the US.
Jack Naito, co-founder and president of Luna Technologies, outlines what will be needed to create the cannabis extraction lab of the future.
This article from Technology Networks breaks down the qualities of the key five psychedelics and the current research projects illuminating their clinical potential.
Nuclear magnetic resonance (NMR) spectroscopy is a physicochemical technique used to obtain structural information about molecules. In this article, Technology Networks considers how it works, what it can tell a lab analyst, and where it is used.
Cannabichromene (CBC) is considered one of the “big six” cannabinoids in terms of cannabis research, with studies suggesting that the cannabinoid could be used to address cancerous tumors, inflammation, and even neurological disease.
“Ketamine is helpful as a medicine, but there’s so much more to be gained by adding the psychotherapy component,” says Dr Reid Robison, Novamind’s chief medical officer.
The extractors at Prospiant answer the key questions and considerations for extraction operators, regardless of whether you are just starting up a business or expanding multi-state locations.
Led by experienced natural products chemists, Psilera Bioscience is on a mission to create new, next-generation psychedelic medicines that can better serve patients’ needs.